Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: Reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone

March 2, 2016

Summary: In opioid-dependent individuals with chronic pain, buprenorphine/naloxone may be an effective therapeutic option using adequate dose and paying attention to withdrawal symptoms and pain.Abstract: Few studies have examined abuse of prescription opioids among individuals with chronic pain under buprenorphine/naloxone (Bup/Nx) maintenance. The current 7-week inpatient study assessed oral oxycodone self-administration by patients with chronic […]

Read the full article →

Reducing the Health Consequences of Opioid Addiction in Primary Care

March 2, 2016

Abstract: Addiction to prescription opioids is prevalent in primary care settings. Increasing prescription opioid use is largely responsible for a parallel increase in overdose nationally. Many patients most at risk for addiction and overdose come into regular contact with primary care providers. Lack of routine addiction screening results in missed treatment opportunities in this setting. […]

Read the full article →

Medical Outcomes Associated with Nonmedical Use of Methadone and Buprenorphine

March 2, 2016

Conclusions: Patients who use methadone nonmedically have higher hospitalization rates, greater ICU utilization rates, and considerably worse medical outcomes when compared with patients who use buprenorphine nonmedically. (Source: The Journal of Emergency Medicine)

Read the full article →

Not Otherwise Specified: Anxiety & the Work of Dr. Robert Hudak

March 2, 2016

Southwest Pennsylvania National Alliance on Mental Illness (NAMI) held its annual conference at the beginning of April, and one of their afternoon breakout workshop presenters was Dr. Robert Hudak, assistant professor of psychiatry at Western Psychiatric Institute & Clinic, University of Pittsburgh. “Pathways to Hope: Shaping a Positive Future in Uncertain Times” was the conference […]

Read the full article →

BUPRENORPHINE HCL AND NALOXONE HCL (Buprenorphine And Naloxone) Tablet [Amneal Pharmaceuticals, LLC]

March 2, 2016

Updated Date: May 21, 2013 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Read the full article →

Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study

March 2, 2016

Conclusions: This is the first study to examine characteristics associated with treatment outcome in patients dependent exclusively on prescription opioids. Characteristics associated with successful outcome after 12 weeks of buprenorphine/naloxone treatment include some that have previously been found to predict heroin-dependent patients’ response to methadone treatment and some specific to prescription opioid-dependent patients receiving buprenorphine/naloxone. […]

Read the full article →

A randomised controlled trial of sublingual buprenorphine–naloxone film versus tablets in the management of opioid dependence

March 2, 2016

Conclusions: The study demonstrated dose equivalence and comparable clinical outcomes between the buprenorphine–naloxone film and tablet preparations, whilst showing improved dispensing times and patient ratings of satisfaction with the film. (Source: Drug and Alcohol Dependence) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Read the full article →

Orexo starts patient dosing in Phase III study of opioid dependence drug

March 2, 2016

Sweden-based Orexo has commenced patient dosing in a Phase III study to evaluate Zubsolv, a sublingual formulation of buprenorphine and naloxone. (Source: Drug Development Technology)

Read the full article →

Buprenorphine/Naloxone Therapy for Opioid Refractory Neuropathic Pain Following Traumatic Amputation: A Case Series

March 2, 2016

(Source: Military Medicine)

Read the full article →

FDA OKs New Formula for Addiction Drug

March 2, 2016

(MedPage Today) — The FDA has approved a new sublingual tablet formulation of the opioid addiction drug buprenorphine-naloxone (Zubsolv), drugmaker Orexo U.S. announced. (Source: MedPage Today Psychiatry)

Read the full article →

← Previous Entries

Next Entries →